Silver Book Fact

Valuing a QALY at $175,000, new drugs that would produce a 5-year delay in Alzheimer’s disease onset for all new cases between 2010 and 2050 would yield a benefit of close to $4 trillion per year.

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • Medicare Costs, Slowed Progression  
  • Medicines Allow Patients to Remain Independent Longer: New Alzheimer’s medicine delays need for costly home care  
  • Impact of Slowed Progression on Severe Stage, Americans Age 65 and Older with Alzheimer’s, 2010-2050  
  • A clinical trial in Europe found that treating Alzheimer’s patients with an Alzheimer’s drug reduced annual treatment costs by $1,000 per patient.  
  • If an Alzheimer’s disease treatment breakthrough that delayed the age of onset by 5 years was introduced in 2015, by 2050 out-of-pocket costs for individuals and families dealing with the…